Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 64

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 16
Chunk 64
---
 Company’s CODM view the Company’s operations and manage its business on the basis of one reportable segment, which is focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system (see Note 1 for a brief description of the Company’s business).The CODM of the Company is the Chief Executive Officer. The CODM assesses the performance of the Company and decides how to allocate resources based upon consolidated net loss that is also reported within the Consolidated Statements of Operations. The measure of segment assets that is reviewed by the CODM is reported within the Consolidated Balance Sheets as consolidated Total assets. The CODM uses consolidated net loss to monitor period-over-period results and decides where to allocate and invest additional resources within the business to continue growth. The following is a summary of the significant expense categories and consolidated net loss details provided to the CODM: 

        Year EndedDecember 31,

        2024

        2023

        Segment operating expenses:

        Research and development:

        GEM-AKI, GEM-CKD and GEM-PSI clinical study expenses
         
        $
        1,681,731

        $
        209,702

        Manufacturing expenses

        390,022

        697,429

        Other program expenses(1)

        77,679

        2,190,493

        Other expenses(2)

        172,369

        282,948

        Personnel expenses (including stock-based compensation)

        1,227,195

        765,330

        General and administrative

        4,426,113

        4,510,762

        Change in fair value of warrant liability

        (81,441
        )

        (8,328,937
        )

        Other (expense) income, net(3)

        7,144,868

        (207,473
        )

        Net loss
         
        $
        (15,038,536
        )
         
        $
        (120,254
        )
       
       (1)Other program expenses include pre-clinical costs and clinical preparation costs primarily for programs GEM-AKI, GEM-CKD and GEM-PSI.(2)Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs.(3)LifeSci Capital LLC judgment expense